JP7670614B2 - 抗原提示好中球由来樹状細胞およびその使用方法 - Google Patents

抗原提示好中球由来樹状細胞およびその使用方法 Download PDF

Info

Publication number
JP7670614B2
JP7670614B2 JP2021542444A JP2021542444A JP7670614B2 JP 7670614 B2 JP7670614 B2 JP 7670614B2 JP 2021542444 A JP2021542444 A JP 2021542444A JP 2021542444 A JP2021542444 A JP 2021542444A JP 7670614 B2 JP7670614 B2 JP 7670614B2
Authority
JP
Japan
Prior art keywords
antigen
neutrophils
cells
population
ova
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021542444A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022518771A (ja
JP2022518771A5 (https=
Inventor
シー． アスター，ジョン
マヤダス，ターニャ
マイソール，ビジャヤ
カレレ，ザビエル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of JP2022518771A publication Critical patent/JP2022518771A/ja
Publication of JP2022518771A5 publication Critical patent/JP2022518771A5/ja
Application granted granted Critical
Publication of JP7670614B2 publication Critical patent/JP7670614B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
JP2021542444A 2019-01-22 2020-01-22 抗原提示好中球由来樹状細胞およびその使用方法 Active JP7670614B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962795498P 2019-01-22 2019-01-22
US62/795,498 2019-01-22
PCT/US2020/014642 WO2020154424A1 (en) 2019-01-22 2020-01-22 Antigen-presenting neutrophil-derived dendritic cells and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2022518771A JP2022518771A (ja) 2022-03-16
JP2022518771A5 JP2022518771A5 (https=) 2023-01-26
JP7670614B2 true JP7670614B2 (ja) 2025-04-30

Family

ID=71735513

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021542444A Active JP7670614B2 (ja) 2019-01-22 2020-01-22 抗原提示好中球由来樹状細胞およびその使用方法

Country Status (3)

Country Link
US (1) US12589140B2 (https=)
JP (1) JP7670614B2 (https=)
WO (1) WO2020154424A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020154424A1 (en) 2019-01-22 2020-07-30 The Brigham And Women's Hospital, Inc. Antigen-presenting neutrophil-derived dendritic cells and methods of use thereof
US20250270326A1 (en) * 2020-12-23 2025-08-28 The Regents Of The University Of California Methods of treating respiratory disorders
JP7607539B2 (ja) * 2021-09-24 2024-12-27 東京エレクトロン株式会社 プラズマ処理装置及び処理方法
EP4601682A1 (en) * 2022-10-13 2025-08-20 The Brigham & Women's Hospital, Inc. Methods and compositions for improving response to immunotherapy

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001061469A (ja) 1999-08-24 2001-03-13 Japan Science & Technology Corp 免疫応答誘導樹状細胞の調製方法
JP2004189724A (ja) 2002-11-29 2004-07-08 Toray Ind Inc 生理活性物質を含む材料およびその製造方法
US20070014795A1 (en) 2004-12-30 2007-01-18 Dhodapkar Madhav V Compositions and methods for enhanced dendritic cell maturation and function
JP2013535508A (ja) 2010-08-13 2013-09-12 ベイラー リサーチ インスティテュート 抗体付きアジュバントを抗原提示細胞に直接的に標的化することをベースにした新規ワクチンアジュバント
JP2017212902A (ja) 2016-05-31 2017-12-07 東ソー株式会社 ＦｃγＲＩＩａをコードするポリヌクレオチド及びＦｃγＲＩＩａの製造方法
US20180250336A1 (en) 2015-08-31 2018-09-06 The Trustees Of The University Of Pennsylvania Compositions and methods of enhancing anti-tumor response using hybrid neutrophils

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4662393A (en) * 1992-07-08 1994-01-31 Schering Corporation Use of gm-csf as a vaccine adjuvant
US7906118B2 (en) * 2005-04-06 2011-03-15 Ibc Pharmaceuticals, Inc. Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
WO2009111396A1 (en) 2008-03-03 2009-09-11 University Of Toledo Dendritic cell precursor populations, dendritic cell populations derived therefrom and uses thereof
ES3000111T3 (en) 2009-02-13 2025-02-27 Immunomedics Inc Intermediates for preparing conjugates with an intracellularly-cleavable linkage
ES2692268T5 (en) * 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
SI2788474T1 (sl) 2012-12-18 2016-01-29 Immunicum Ab Ko-diferenciacija monocitov iz alogenskih darovalcev
WO2020154424A1 (en) 2019-01-22 2020-07-30 The Brigham And Women's Hospital, Inc. Antigen-presenting neutrophil-derived dendritic cells and methods of use thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001061469A (ja) 1999-08-24 2001-03-13 Japan Science & Technology Corp 免疫応答誘導樹状細胞の調製方法
JP2004189724A (ja) 2002-11-29 2004-07-08 Toray Ind Inc 生理活性物質を含む材料およびその製造方法
US20070014795A1 (en) 2004-12-30 2007-01-18 Dhodapkar Madhav V Compositions and methods for enhanced dendritic cell maturation and function
JP2013535508A (ja) 2010-08-13 2013-09-12 ベイラー リサーチ インスティテュート 抗体付きアジュバントを抗原提示細胞に直接的に標的化することをベースにした新規ワクチンアジュバント
US20180250336A1 (en) 2015-08-31 2018-09-06 The Trustees Of The University Of Pennsylvania Compositions and methods of enhancing anti-tumor response using hybrid neutrophils
JP2017212902A (ja) 2016-05-31 2017-12-07 東ソー株式会社 ＦｃγＲＩＩａをコードするポリヌクレオチド及びＦｃγＲＩＩａの製造方法

Also Published As

Publication number Publication date
JP2022518771A (ja) 2022-03-16
WO2020154424A1 (en) 2020-07-30
US20220106566A1 (en) 2022-04-07
US12589140B2 (en) 2026-03-31

Similar Documents

Publication Publication Date Title
Mysore et al. FcγR engagement reprograms neutrophils into antigen cross-presenting cells that elicit acquired anti-tumor immunity
JP7587858B2 (ja) ヒトｃｄ１３７に結合するアゴニスト性抗体およびその使用
US11026973B2 (en) Engineered phagocytic receptor compositions and methods of use thereof
JP7670614B2 (ja) 抗原提示好中球由来樹状細胞およびその使用方法
Caminschi et al. The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement
US11154600B2 (en) Use of anti-CD47 agents to enhance immunization
Sancho et al. Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin
AU2008278831B2 (en) Immune modulation via C-type lectin
EP3656443B1 (en) Use of trl agonist and anti-cd47 agent to enhance phagocytosis of cancer cells
He et al. A novel human cancer vaccine elicits cellular responses to the tumor-associated antigen, human chorionic gonadotropin β
Josephs et al. IgE immunotherapy: a novel concept with promise for the treatment of cancer
JP4846718B2 (ja) ヒト樹状細胞に結合するモノクローナル抗体とβヒト絨毛性性腺刺激ホルモンを含むワクチン結合体
JP2011513479A (ja) モノクローナル抗体、及びその（ｔｈｅｒｏｆ）方法
JP2017507922A (ja) 抗体のためおよび抗体が充填された樹状細胞を介した療法のための方法および組成物
JP2012102122A (ja) Ｉｌ−２１およびモノクローナル抗体治療を用いる癌を処置する方法
US11851497B2 (en) CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
EP4601682A1 (en) Methods and compositions for improving response to immunotherapy
Tunheim et al. Human CD14 is an efficient target for recombinant immunoglobulin vaccine constructs that deliver T cell epitopes
Watkins Antibody Targeting of Antigen to Endogenous Immune Surveillance Pathways for the Induction of Tolerance
Singh Glycan-Lectin duet, Novel strategies for DC-targeting
HK40027822A (en) Use of trl agonist and anti-cd47 agent to enhance phagocytosis of cancer cells
HK40027822B (en) Use of trl agonist and anti-cd47 agent to enhance phagocytosis of cancer cells
Ho Antigen handling and cross-presentation by dendritic cells
Geldart Efficacy and toxicity of anti-CD40 monoclonal antibodies in the treatment of malignancy
Schultz Defining adapter proteins that regulate Fc-epsilon-RI-mediated antigen uptake during IgE-mediated cross-presentation by dendritic cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230113

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230113

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240308

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240619

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240910

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250210

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250415

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250417

R150 Certificate of patent or registration of utility model

Ref document number: 7670614

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150